125 related articles for article (PubMed ID: 37437018)
21. Amurensin G Sensitized Cholangiocarcinoma to the Anti-Cancer Effect of Gemcitabine via the Downregulation of Cancer Stem-like Properties.
Na YJ; Lee HK; Choi KC
Nutrients; 2023 Dec; 16(1):. PubMed ID: 38201903
[TBL] [Abstract][Full Text] [Related]
22. Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness.
Wattanawongdon W; Hahnvajanawong C; Namwat N; Kanchanawat S; Boonmars T; Jearanaikoon P; Leelayuwat C; Techasen A; Seubwai W
Int J Oncol; 2015 Jul; 47(1):398-410. PubMed ID: 25998688
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapeutic resistant cholangiocarcinoma displayed distinct intratumoral microbial composition and metabolic profiles.
Sitthirak S; Suksawat M; Phetcharaburanin J; Wangwiwatsin A; Klanrit P; Namwat N; Khuntikeo N; Titapun A; Jarearnrat A; Sangkhamanon S; Loilome W
PeerJ; 2022; 10():e13876. PubMed ID: 35990899
[TBL] [Abstract][Full Text] [Related]
24. Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy.
Zhang X; Tang H; Fan J; Wang R; Han Y; Su S; Gan Y; Peng F; Rao M; Zhang J; Li B; Yang X
Front Immunol; 2022; 13():1051130. PubMed ID: 36618353
[TBL] [Abstract][Full Text] [Related]
25. Metabolic Phenotyping Predicts Gemcitabine and Cisplatin Chemosensitivity in Patients With Cholangiocarcinoma.
Suksawat M; Phetcharaburanin J; Klanrit P; Namwat N; Khuntikeo N; Titapun A; Jarearnrat A; Vilayhong V; Sa-Ngiamwibool P; Techasen A; Wangwiwatsin A; Mahalapbutr P; Li JV; Loilome W
Front Public Health; 2022; 10():766023. PubMed ID: 35223723
[TBL] [Abstract][Full Text] [Related]
26. Photochemical Internalization of Gemcitabine Is Safe and Effective in Locally Advanced Inoperable Cholangiocarcinoma.
Trojan J; Hoffmeister A; Neu B; Kasper S; Dechêne A; Jürgensen C; Schirra J; Jakobs R; Palmer D; Selbo PK; Olivecrona H; Finnesand L; Høgset A; Walday P; Sturgess R
Oncologist; 2022 Jun; 27(6):430-e433. PubMed ID: 35675633
[TBL] [Abstract][Full Text] [Related]
27. Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression.
Lu D; Han C; Wu T
Gastroenterology; 2011 Jun; 140(7):2084-94. PubMed ID: 21354147
[TBL] [Abstract][Full Text] [Related]
28. miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.
Okamoto K; Miyoshi K; Murawaki Y
PLoS One; 2013; 8(10):e77623. PubMed ID: 24147037
[TBL] [Abstract][Full Text] [Related]
29. Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma.
Cho S; Lee TS; Song IH; Kim AR; Lee YJ; Kim H; Hwang H; Jeong MS; Kang SG; Hong HJ
PLoS One; 2017; 12(2):e0170078. PubMed ID: 28166242
[TBL] [Abstract][Full Text] [Related]
30. Optimal combination of gemcitabine, sorafenib, and S-1 shows increased efficacy in treating cholangiocarcinoma in vitro and in vivo.
Li H; Zhang Z; Zhou Z; Ding X; Zhou G
Anticancer Drugs; 2016 Aug; 27(7):600-8. PubMed ID: 27035747
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases.
Lee MA; Woo IS; Kang JH; Hong YS; Lee KS
Jpn J Clin Oncol; 2004 Sep; 34(9):547-50. PubMed ID: 15466829
[TBL] [Abstract][Full Text] [Related]
32. GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway.
Jang DK; Lee YG; Chan Chae Y; Lee JK; Paik WH; Lee SH; Kim YT; Ryu JK
Biochem Biophys Res Commun; 2020 Sep; 529(4):1242-1248. PubMed ID: 32819590
[TBL] [Abstract][Full Text] [Related]
33. LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma.
Conboy CB; Yonkus JA; Buckarma EH; Mun DG; Werneburg NW; Watkins RD; Alva-Ruiz R; Tomlinson JL; Guo Y; Wang J; O'Brien D; McCabe CE; Jessen E; Graham RP; Buijsman RC; Vu D; de Man J; Ilyas SI; Truty MJ; Borad M; Pandey A; Gores GJ; Smoot RL
J Hepatol; 2023 Jan; 78(1):142-152. PubMed ID: 36162702
[TBL] [Abstract][Full Text] [Related]
34. A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO).
Virchow I; Treckmann JW; Prasnikar N; Linden G; Markus P; Schumacher B; Albers D; Herold T; Ting S; Schmidt H; Radunz S; Wiesweg M; Siveke J; Schuler M; Kasper S
Oncol Res Treat; 2023; 46(3):89-99. PubMed ID: 36623497
[TBL] [Abstract][Full Text] [Related]
35. Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells.
Buranrat B; Prawan A; Kukongviriyapan U; Kongpetch S; Kukongviriyapan V
World J Gastroenterol; 2010 May; 16(19):2362-70. PubMed ID: 20480521
[TBL] [Abstract][Full Text] [Related]
36. Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report.
Marciano R; Servetto A; Bianco C; Bianco R
J Med Case Rep; 2017 Sep; 11(1):273. PubMed ID: 28946921
[TBL] [Abstract][Full Text] [Related]
37. Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma.
Zhang GF; Qiu L; Yang SL; Wu JC; Liu TJ
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32140709
[TBL] [Abstract][Full Text] [Related]
38. Can thymidine phosphorylase be a predictive marker for gemcitabine and doxifluridine combination chemotherapy in cholangiocarcinoma?: case series.
Kang MH; Lee WS; Go SI; Kim MJ; Lee US; Choi HJ; Kim DC; Lee JH; Kim HG; Bae KS; Cho JM
Medicine (Baltimore); 2014 Dec; 93(28):e305. PubMed ID: 25526478
[TBL] [Abstract][Full Text] [Related]
39. miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator.
Zhu H; Han C; Lu D; Wu T
Am J Pathol; 2014 Oct; 184(10):2828-39. PubMed ID: 25239565
[TBL] [Abstract][Full Text] [Related]
40. Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.
Sato J; Kimura T; Saito T; Anazawa T; Kenjo A; Sato Y; Tsuchiya T; Gotoh M
J Hepatobiliary Pancreat Sci; 2011 Sep; 18(5):700-11. PubMed ID: 21451941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]